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ABSTRACT
MYCN activation, mainly by gene amplification, is
one of the most frequent molecular events in neuro-
blastoma (NB) oncogenesis, and is associated with
increased malignancy and decreased neuronal
differentiation propensity. The frequency of conco-
mitant loss of heterozygosity at the 1p36.3 locus,
which harbours the p53 anti-oncogene homologue
TP73, indicates that MYCN and p73 alterations may
cooperate in the pathogenesis of NB. We have
previously shown that p73 isoforms are deregulated
in NB tumours and that TAp73 co-operates syner-
gistically with p53 for apoptosis of NB cells,
whereas "Np73 activates the expression of neuronal
differentiation genes such as BTG2. Herein, using
both ectopic expression and RNA interference-
mediated silencing of p73 in MYCN amplified NB
cells, we show that p73a isoforms inhibit MYCN
expression at both transcript and protein levels,
in spite of transactivator effects on MYCN promoter.
To explain this paradox, we found that TAp73a
exerts negative post-transcriptional effects
leading to reduced MYCN mRNA stability. RNA
immunoprecipitation experiments suggest that
this dominant inhibitory post-transcriptional effect
could be due to an interaction between the p73
protein and MYCN mRNA, a hypothesis also raised
for the regulation of certain genes by the p53
protein.
INTRODUCTION
Neuroblastomas (NB), paediatric cancers developing
from peripheral sympathetic neurons, frequently display
ampliﬁcation of the MYCN proto-oncogene, which
strongly correlates with advanced disease stage and poor
outcome (1,2). The MYCN protein was shown to play a
crucial role in NB tumorigenesis, notably by promoting
cell proliferation and impeding diﬀerentiation (3).
NB also recurrently present loss of heterozygosity on
chromosome 1p36, a region altered in many types of can-
cers (4–6). The p53 anti-oncogene homologue TP73 was
discovered at this locus (7). Although the remaining TP73
allele is only exceptionally mutated, we and others have
shown that quantitative and qualitative p73 alterations
contribute to the pathogenesis of NB, albeit not as a clas-
sical tumour suppressor (8,9).
Inadditiontostructural homology,p73alsosharesfunc-
tional homology with p53, TAp73 being notably capable to
transactivate many p53-responsive genes. However, in p73,
the C-terminal region is, unlike that of p53, composed of a
Sterile Alpha Motif (SAM) domain and a transactivation
inhibitor (TI) domain (Supplementary Figure S1). The
SAM domains are widespread among eukaryotes and bac-
teria (reviewed in 10), have been identiﬁed in nearly 1000
proteins and are potentially involved in a large spectrum
of biological processes. SAM domains were notably impli-
cated in protein–protein interactions, and the SMAUG-
like SAM domains have recently been showed to bind
speciﬁc RNA sequences named SAM response elements
(SRE) (11). The SAM domain of p73 was shown to play
a transcription inhibitory role by preventing, in concert
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activation domain of p73 (12). It could also mediate other
biological functions through its capacity to interact with
lipid membranes (13).
The p73 gene encodes multiple isoforms, due to alterna-
tive promoter usage and mRNA splicing (Supplementary
Figure S1). TAp73 isoforms, harbouring a transactivating
domain (TA), are known to transactivate p53 responsive
genes and to induce apoptosis and growth arrest, whereas
N-terminal truncated Np73 isoforms, lacking the TA
domain, can act as dominant-negative towards p53 and
TAp73 (14,15). Splicing at the 30 end of p73 transcripts
gives rise to C-terminal protein variants containing
(isoforms a) or not (isoforms b and others) the SAM
domain and the TI region.
Interferon-g was shown to activate p73, which in turn
activates caspase-1 in Hela cells (16). Additionally, inter-
feron-g is known to down-regulate MYCN mRNA in NB
cells treated with retinoic acid (17). Moreover, TAp73-
induced diﬀerentiation of mouse neuroblastoma cells
was associated with MYCN protein down-regulation
(18). These observations suggested that p73 can inhibit
MYCN expression in NB cells, without indicating whether
the regulation operates at the transcriptional or post-
transcriptional level. The present study aims to answer
to these questions and to elucidate the molecular mecha-
nism involved.
MATERIALS AND METHODS
Constructs and siRNA
The plasmid constructs pcDNA-TAp73a, pcDNA-
TAp73b, pcDNA-Np73a and pcDNA-Np73b,
obtained by cloning the various cDNA into the pcDNA3-
Neo vector (Invitrogen), were kindly provided by Dr
Mourad Kaghad (Sanoﬁ-Aventis Recherche, Labe ` ge,
France). The empty pcDNA3-Neo vector was used as a
control. The pGL3-NMYC-Luc reporter construct, con-
taining the proximal MYCN promoter cloned in front of
the ﬁreﬂy luciferase cDNA, as described (19), was a kind
gift from Drs Marianne Kim and William Carroll (Mount
Sinai School of Medicine, New York). The pGL3-Luc
vector (Promega) was used as a control. For gene silencing
experiments, we used small interfering RNA (siRNA), con-
sisting of chemically synthesized 21-mer oligoribonucleo-
tide duplexes (QIAGEN). As a non-silencing control, we
designed a siRNA (sequence: 5’-AAAGACGGTGGTC
ATTACCTAGT-3’) targeting the RFP mRNA (accession
number AF168419, encoding coral red ﬂuorescence pro-
tein); the TAp73 siRNA, targeting exon 3 of the human
TP73 gene, was as previously described (20).
Cell culture, transient transfectionsand chemical treatments
The human neuroblastoma cell lines SH-SY5Y, SK-N-AS
and IMR32 were purchased from the European Collection
of Cell Cultures (ECACC, Wiltshire, UK). The Kelly
and LAN-1 cells were respectively provided by Dr Jean-
Philippe Deslys (Commissariat a ` l’Energie Atomique,
Fontenay-Aux-Roses, France) and Dr Nicole Gross
(Paediatric Oncology Research, Lausanne, Switzerland).
IMR32, Kelly and LAN-1 cells were grown in RPMI
medium supplemented with 10mM Hepes, 10% fetal
calf serum and 10mg/ml of gentamicine (GIBCO). Other
cell lines were grown in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal calf serum and
10mg/ml of gentamicine. Cells were maintained at 378C
in a humidiﬁed incubator with 5% CO2.
Plasmids were transfected into cells plated in 6 well
plates using Lipofectamine 2000 (Invitrogen) and siRNA
using Oligofectamine (Invitrogen), according to the man-
ufacturer’s instructions. For luciferase assays, plasmids
and siRNA were cotransfected using Lipofectamine
2000. For plasmids transfections, cells were plated at a
density of 10
6cells/well, were transfected the following
day with 4mg of plasmid and harvested 2 days later for
protein or RNA analyses. For siRNA transfections, cells
were plated at a density of 2 10
5cells/well for Kelly or
LAN-1 cells and 5 10
5cells/well for SH-SY5Y cells.
Cells were transfected the following day with siRNAs, at
a ﬁnal concentration of 200nM, and collected 3 days later
for protein and RNA analyses.
To measure MYCN transcripts half-life, cells were
treated 48h after transfection with 5mM of Actinomycin
DtoblockmRNAsynthesis,thenharvestedafter0.5,1,2,3
and 6h of treatment for RNA analysis, as described below.
At least three independent series of transfections, with
duplicates for each condition, were performed and
analysed.
RNA extraction, reverse transcription and
polymerase reaction
Total RNA was extracted and treated with DNase I using
the RNeasy mini kit (QIAGEN), according to the manu-
facturer’s instructions. RNA (1mg) was converted into
single strand complementary DNA (cDNA) using super-
script II reverse transcriptase (Invitrogen). Reactions in
which the reverse transcriptase was omitted (RT-) were
used as negative controls. Quantitative reverse transcrip-
tion-polymerase chain reaction (qRT–PCR) was per-
formed in a ﬁnal volume of 25ml containing 25ng of
cDNA or RT- as templates, 10pmol of each primer
and 12.5ml of SYBR-Green master mix (Applied
Biosystems). The sets of primers used were: for MYCN:
50-CACCCTGAGCGATTCAGATGA-30 and 50-CCGG
GACCCAGGGCT-30; for c-MYC:5 0-CCACCAGCAGC
GACTCTGA-30 and 50-GCAGAAGGTGATCCAGAC
TC-30; for TAp73:5 0-GCACCACGTTTGAGCACCT
CT-30 and 5’-GCAGATTGAACTGGGCCATGA-30; for
DNp73:5 0-CAAACGGCCCGCATGTTCCC-30 and
50-TTGAACTGGGCCGTGGCGAG-30; for p73Dex2-3:
50-TGCAGGCCCAGTTCAATCTGC-30 and 50-TGCGT
GTTGGAGGGGATGACA-30; for GAPDH:5 0-AGCTC
ACTGGCATGGCCTTC-30 and 50-ACGCCTGCTTCAC
CACCTTC-30; for 18S rRNA: 50-CGGCTACCACATC
CAAGGAA-30 and 50-GCTGGAATTACCGCGGCT-30.
The ampliﬁcation reactions were performed and moni-
tored in real-time using the ABI Prism 7000 Sequence
Detection system (Applied Biosystems). MYCN and p73
mRNA levels were normalized between samples
using GAPDH mRNA and 18S rRNA as references.
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cDNA or RT-controls were ampliﬁed in a ﬁnal volume
of 10ml containing 0.25 units of AmpliTaq Gold DNA
polymerase (Roche Applied Science) containing 1.75mM
MgCl2, 200mM of each nucleotide and 0.5mM of each
primer. We used this method to determine the relative
transcript levels of a and b isoforms of p73, with primers
ﬂanking exon 13 of the TP73 gene, which is spliced out in
b but not a isoforms of p73: forward: 50-CCGAC
CCCAGCCTCGTCAG-30; reverse: 50-CTGAGCCGCC
GATGGA-30. Ampliﬁcation of GAPDH was used as a
control for normalization. PCR reactions consisted of an
initial denaturation step of 10min at 948C, then 30 cycles
(TP73) or 20 cycles (GAPDH)o f3 0sa t9 4 8C, 30s at 608C
and 1min 10s at 728C using a PTC-100 thermocycler
(MJ-Research). The number of cycles was chosen to be in
the exponential phase of the ampliﬁcation. PCR products
weresubjectedtoelectrophoresisin1.8%agarosegels,then
stained for 30min with SYBR-Green I (Molecular
Probes). Gels were visualized using a Fujiﬁlm FLA-3000
scanner (FUJI), and the ampliﬁed fragments were quanti-
ﬁed with the IMAGE J software.
Westernblot
Immunoblotting was carried out as described previ-
ously (21). Thirty to 50mg of total protein were separated
by 4–12% sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis, and transferred onto nitrocellulose ﬁlters.
After saturation, the membranes were incubated with pri-
mary antibodies diluted in Tris-buﬀered saline (TBS) con-
taining 0.1% Tween-20 and 5% skim milk. The primary
antibodies used, all mouse monoclonal, except for p73
(rabbit polyclonal), were: anti-p73 (a kind gift from
Dr Mourad Kaghad, Sanoﬁ-Aventis Recherche, Labe ` ge,
France), anti-p73b (Ab-3, Oncogene Research), anti-
MYCN (Ab-1, Oncogene Research), anti-p53 (DO-7,
DAKO), all 4 at a dilution of 1/1000 and anti-b-actin
(Chemicon) at a dilution of 1/5000 as a loading control.
After washes in TBS-tween, incubation with a secondary
horseradish peroxidase coupled anti-mouse or anti-rabbit
antibody (at a dilution of 1/2000 except for b-actin,
1/10000) and subsequent washes, protein bands were
revealed using ECL reagent (GE Healthcare), except for
p73 for which we used Immobilon Western (Millipore).
Luciferase reporter assays
For luciferase reporter assays, cells were seeded in tripli-
cates in 12-well plates at a density of 3 10
5 cells/well. The
following day, cells were co-transfected with 0.5mgo f
either control or MYCN promoter containing pGL3-Luc
reporter constructs, together with 1mg of expression vec-
tors or 200pmol of siRNA, using Lipofectamine 2000, as
described above. Twenty-four hours after transfection,
cells were lysed with passive lysis buﬀer (100ml/well),
provided with the ‘Luciferase assay kit’ (Promega).
Fireﬂy luciferase activity was measured according to the
manufacturer’s protocol using Microlumat LB96P lumin-
ometer (EG&G Berthold Instruments).
Chromatin and RNA immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed
as described in one of our recent reports (22), using 4mg
of mouse monoclonal antibody raised against p73
(Ab2, Calbiochem). Non-precipitated chromatin and
chromatin precipitated in the presence of a pre-immune
mouse IgG were used as positive and negative controls,
respectively. The precipitated chromatin was then puriﬁed
by phenol–chloroform extraction and ethanol precipita-
tion. Interaction between the p73 protein and MYCN
gene promoter region was searched by PCR using the
following pairs of primers: ATGCTGCTGCTGGA
CAGAG ( 1237) and TGATTCCAAACTGTTGAAG
GG ( 1009); CCCTCGTAGCTCGCACTTATT ( 668)
and AAAGAAGGGTAGTCCGAAGGT ( 518); CGG
GTGTGTCAGATTTTTCAGT ( 61) and TGCTCGG
CTCCAACACAGTTC (+64), numbered nucleotide
referring to the transcription start site. PCR conditions
(28 cycles, using 1/40th of the immunoprecipitated
DNA as a template) and SYBR-Green I-stained agarose
gel analysis were performed as described in the semi-
quantitative RT–PCR section.
ForRNAimmunoprecipitation(RNA IP),10
7cellswere
lysed with 300ml polysome lysis buﬀer (KCl 100mM,
MgCl2 5mM, Hepes pH7 10mM, Nonidet P-40
0.5%) containing RNase and protease inhibitors. One
hundred microlitres of cellular extracts were kept as non-
immunoprecipitated input control. Fifty microlitre of pro-
tein G Dynabeads (Invitrogen) were pre-incubated for 1h
in 200ml of IP buﬀer containing 50mM of Tris pH7.4,
150mM NaCl, 5mM MgCl2 and 0.05% Nonidet p-40.
We then added 4mg of control or p73 antibodies (see the
ChIPsection above)andhomogenized themix overnight at
48C. One hundred microlitres of cellular extracts were
added to each control and p73 antibody containing
mixes, and immunoprecipitations were carried out for 2h
at room temperature under constant homogenization. The
beads were washed 6 times using IP buﬀer (see above), then
treated with 30mg of proteinase K diluted in 100mlo fI P
buﬀer containing 0.1% SDS. Immunoprecipitated RNA
was then puriﬁed using phenol/chloroform extraction fol-
lowed by ethanol precipitation. Interaction between the
p73 protein and MYCN transcript was searched by quan-
titative reverse transcription-polymerase chain reaction
(qRT–PCR) analysis, as described above.
RESULTS
p73 inhibits MYCN expression at bothmRNA
and proteinlevels
In order to investigate the impact of p73 on MYCN expres-
sion in neuroblastoma (NB) cells, we selected, among a
panelofNBcelllines,MYCNampliﬁedandoverexpressing
cells with diﬀerent p73 status. Most of the tested NB cell
lines overexpress MYCN, at the RNA and protein levels
(Figure 1A and B). Among MYCN overexpressing cell
lines, some, such as IMR32, lack endogenous p73 expres-
sion, while others, such as Kelly and LAN-1, express mod-
erate or high levels of p73 (Figure 1A and B). We thus ﬁrst
4224 Nucleic Acids Research, 2008, Vol. 36, No. 13used IMR32 cells to test the eﬀect of ectopic p73 expression
on MYCN levels. Transfection of a TAp73a expression
vector in these cells led to a clear inhibition of MYCN
protein levels (Figure 2A, top). The N- and C-terminal-
truncated Np73a and TAp73b isoforms produced a simi-
lar or even more pronounced inhibitory eﬀect on MYCN
protein levels. Consistent with the ectopic expression data,
RNA-interference-mediated silencing of endogenous
TAp73 in Kelly and LAN-1 cell lines was associated with
signiﬁcant MYCN protein levels increase (Figure 2B, top).
The TP73 siRNA used in these and subsequent experi-
ments targets exon 3 of the gene (20) and thus speciﬁcally
inhibit the TA isoforms, both a and b. At the RNA level,
the Kelly and LAN-1 cells express the TA (minor) and
Dex2-3 (major) TP73 50 isoforms, and both the a and b
30 TP73 splice variants, in equal proportions for LAN-1
(Figure 1A). However, western blot analyses indicate
that, at the protein level, these two cell lines express
TAp73a but not the C-terminal truncated TAp73b isoform
(Figure 2B, top), as conﬁrmed with a p73b-speciﬁc anti-
body that did not detect any band in these cells (data not
shown). Although a long exposure of the western blots
indicated that LAN-1 cells express both TA and Np73
protein isoforms (Figure 1B), another blot with shorter
exposure showed that these cells express mainly the full-
length TAp73 protein isoform (Figure 2B, top). A distinct
siRNA targeting TAp73, although having a lower silencing
eﬃciency than the previous one, led to similar eﬀects on
MYCN levels but at a lesser extent (Supplementary
Figure S2). Based on these observations, we conclude
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TAp73a isoform. Considering the diﬀerences in the p53
status of the studied cell lines (Figure 1), the inhibitory
eﬀect of p73 on MYCN protein levels appears to be inde-
pendent of p53. Indeed, as examples, p73 isoforms repress
MYCN levels in IMR32 cells, which express wild type p53,
and in LAN-1 and IGR-N-91 cells, which respectively lack
p53 protein expression or express a mutant p53 protein.
We then examined the impact of p73 on MYCN mRNA
levels.Ectopicexpressionofp73aandbisoformsinIMR32
cells was associated with a decrease in MYCN mRNA
ranging from 1.5- to 2.5-fold (Figure 2A, bottom), indicat-
ingthatthe regulation occurs atthe transcriptional or post-
transcriptional level. In agreement with these observations,
silencing of endogenous TAp73a in Kelly and LAN-1 cells,
respectively led to a 1.5- and 3-fold increase in MYCN
mRNA levels (Figure 2B, bottom). Ectopic expression of
both TA- and N-p73a isoforms also caused a decrease in
MYCNmRNAlevelsinIGR-N-91,anotherMYCNampli-
ﬁedNBcellline thatlacksendogenousp73(Supplementary
Figure S3). Therefore, although to a diﬀerent extent,
TAp73a, Np73a and TAp73b all inhibited MYCN
mRNA accumulation.
p73a, butnotbisoforms, leadto activationof MYCN
gene transcription withoutbinding to its promoter
Based on its inhibitory eﬀects on MYCN mRNA levels, we
thentestedtheimpactofp73onMYCNgenetranscription.
Surprisingly,ectopicexpressionofTAp73ainIMR-32cells
led to a >2-fold increase in the activity of a MYCN pro-
moter reporter construct (Figure 3A). Interestingly, the
Np73a isoform yielded an even stronger (>5-fold)
MYCN promoter activation, indicating that the N-term-
inal transcriptional activator (TA) domain of p73 is not
required and that p73a leads to MYCN gene transactiva-
tion via an alternative mechanism (Figure 3A). On the con-
trary,ectopicTAp73bexpressioncauseda4-foldinhibition
of MYCN promoter activity in IMR32 cells (Figure 3A).
MYCN promoter activation in response to ectopic expres-
sion of TAp73a and Np73a was similarly observed in
IGR-N-91 and LAN-5 cells exhibiting little or no detect-
able endogenous p73 protein, respectively, whereas no sig-
niﬁcant eﬀects were observed in LAN-1 cells expressing
high endogenous p73 (Figures 1 and 3A). However,
TAp73b retained its inhibitory eﬀects on MYCN promoter
in LAN-1 like in the other cell lines (Figure 3A). Recipro-
cally, depletion of endogenous TAp73a in Kelly and
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4226 Nucleic Acids Research, 2008, Vol. 36, No. 13LAN-1 cells led to an approximately 2-fold decrease in
MYCN promoter activity (Figure 3B).
Our observations demonstrate that, although p73a iso-
forms lead to MYCN promoter activation, the global
impact of p73a on MYCN mRNA levels is inhibitory,
suggesting that p73a exerts a double eﬀect on MYCN
gene expression: a positive transcriptional eﬀect and an
inhibitory post-transcriptional eﬀect, the latter being
dominant. On the other hand, p73b acts through a diﬀer-
ent mechanism, leading to MYCN repression at the tran-
scriptional level.
We then investigated whether the transcriptional regu-
lation of MYCN by p73 was direct using the chromatin
immunoprecipitation (ChIP) approach to test the possible
binding of the p73 protein to MYCN promoter. We per-
formed ChIP analysis on LAN-1 cells that express high
endogenous p73 (Figure 1). Immunoprecipitated DNA
was ampliﬁed by polymerase chain reaction (PCR) using
3 pairs of primers spanning the transcription start site and
proximal (1.2kb) promoter region of the MYCN gene. We
found no signiﬁcant binding of the p73 protein to the
MYCN promoter, while a PCR analysis of the same
ChIP extracts demonstrated binding of p73 to the
p75
NTR promoter (Supplementary Figure S4). These
results indicate that the transcriptional activation of
MYCN by p73 may not be direct, although we cannot
exclude that p73 interacts with MYCN gene regulatory
elements located outside of the proximal promoter region.
p73aisoforms activate MYCN promoter independently
ofMYCN protein expression
Certain transcriptional targets induced by MYCN, in
particular the MYC superfamily transcription factor
MXI1, are known to repress MYCN promoter (23–25).
We hypothesized that the positive eﬀects of p73 we
observed on MYCN promoter could be due to such an
indirect negative feedback loop. Namely, as p73 impedes
on MYCN protein levels, a resulting down-regulation of
the repressive factor MXI1 could lead to increased MYCN
promoter activity. To address this hypothesis, we investi-
gated the impact of p73 on MYCN promoter activity in
two MYCN non-ampliﬁed cell lines (SK-N-AS and
SH-SY5Y, respectively harbouring two and three copies
of the MYCN gene) that lack signiﬁcant MYCN protein
expression. Ectopic expression of both TA- and N-p73a
isoforms resulted in MYCN promoter activation in p73-
negative SK-N-AS cells, while silencing of the endogenous
TAp73a in SH-SY5Y cells led to diminished MYCN pro-
moter activity (Figure 3C and D). These observations
indicate that p73a isoforms lead to MYCN promoter
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Figure 3. P73a but not b isoforms lead to activation of MYCN gene transcription in human neuroblastoma cells. Eﬀects of ectopic expression of p73
isoforms (A and C) or small interfering RNA (siRNA)-mediated depletion of endogenous TAp73 (B and D)o nMYCN gene promoter activity in
neuroblastoma cell lines. Values represent the mean Luciferase reporter gene activity SEM of three replicates.
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and of a negative feedback loop.
The p73protein interacts withMYCN mRNA
The p53 protein has been shown to interact with RNA (26).
Although the exact role of these interactions is still unclear,
it has been suggested that they are putatively involved in
post-transcriptional gene regulation by p53. Given our
observations indicating that the closely related p73a pro-
tein post-transcriptionally inhibits the MYCN gene, we
investigated whether this protein could bind to MYCN
transcripts. To address this question, we performed an
RNA immunoprecipitation (RNA IP) analysis on LAN-1
cells that highly express both endogenous p73 protein and
MYCN mRNA (Figure 1). Immunoprecipitated RNA was
puriﬁed and p73-RNA interactions were evaluated by
quantitative reverse-transcription polymerase chain reac-
tion (qRT–PCR). Background MYCN mRNA could be
detectedinthe RNAIP performedwithacontrolantibody,
but a much higher amount of MYCN transcript was
recovered with a p73 antibody (Figure 4). These results
indicate that the p73 protein likely interacts with MYCN
mRNA and that this interaction could play a role in the
inhibitory post-transcriptional regulation exerted by p73
on MYCN.
p73aimpairs MYCN mRNA stability
In order to further characterize the post-transcriptional
inhibition of MYCN by p73, we investigated the impact
of p73 on MYCN transcript stability. To assess MYCN
mRNA half-life, we treated NB cells with the transcription
inhibitor Actinomycin D. We then harvested cells for RNA
extraction at diﬀerent time points ranging from 0.5 to 6h
of treatment, and measured MYCN mRNA levels by
qRT–PCR. As we observed that MYCN RNA decays in
an exponential manner (Supplementary Figure S5), we
plottedthelogarithmofMYCNmRNAlevelsasafunction
of time. The slope of the straight lines obtained allowed us
to calculate the half-life of MYCN mRNA in diﬀerent
experimental conditions (Figure 5). Ectopic expression of
both TAp73a and Np73a in IMR-32 cells led to a faster
MYCN mRNA decay (35 and 25% increase, respectively),
whereas TAp73b had almost no signiﬁcant (<10%) eﬀects
(Figure 5A). Reciprocally, silencing of endogenous
TAp73a augmented by >50% MYCN mRNA half-life in
both Kelly and LAN-1 cell lines (Figure 5B and C). Our
observations therefore establish that p73a inhibits MYCN
transcript stability.
The post-transcriptional inhibition exerted byp73 does not
extend to thewhole MYC genesfamily
We then investigated whether the opposite transcriptional
and post-transcriptional eﬀects of p73 in NB cells was spe-
ciﬁc to MYCN. The latter belonging to the MYC proto-
oncogenes family, whose sequences are very similar, we
tested the impact of p73 on c-MYC, another member of
this gene family. We addressed this question in the
SH-SY5Y MYCN non-ampliﬁed NB cell line that exhibits
low MYCN mRNA levels and expresses 20-fold more
c-MYC (MYCN and c-MYC transcript levels, normalized
toGAPDH,beingrespectively0.76 10
 3and16.3 10
 3,
see controls on Figure 6A). MYCN protein was hardly
detectable in SH-SY5Y cells (Figure 1B). Nevertheless,
qRT–PCR analysis showed that depletion of endogenous
p73 in these cells resulted in MYCN mRNA levels increase,
duetohalf-lifeaugmentation(Figure6A–D)surpassingthe
transcription inhibition (Figure 3D), as observed in Kelly
and LAN-1 cells (Figures 2B, 3B, 5B and C). On the con-
trary, depletion of endogenous p73 in SH-SY5Y cells
yielded an inhibition of both c-MYC mRNA and
protein levels without altering c-MYC mRNA half-life
(Figure 6A–D), indicating that p73 positively regulates
c-MYC expression at the transcriptional level. Therefore,
the negative post-transcriptional regulation exerted by p73
on MYCN mRNA is quite speciﬁc and does not operate on
closely related genes.
DISCUSSION
Our study shows that the p53 family member p73 exerts
opposite transcriptional and post-transcriptional regula-
tory eﬀects on MYCN gene expression in neuroblastoma
cells. Indeed, although p73 isoforms TA-a and N-a lead
to MYCN promoter transactivation, both proteins inhibit
MYCN transcript levels through a dominant post-tran-
scriptional mechanism leading to MYCN mRNA decay,
and consequently reduced protein expression. Np73 iso-
forms, although lacking the N-terminal transactivating
(TA) domain (Supplementary Figure S1), do not act sys-
tematically as dominant negatives and can activate the
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Figure 4. The p73 protein interacts with MYCN mRNA. Binding of
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4228 Nucleic Acids Research, 2008, Vol. 36, No. 13expression of certain genes. For example, Np73a can
transactivate the BTG2
TIS21/PC3 gene in NB cell lines
expressing wild-type p53 (27) and Np73b is active in
gene transactivation and growth suppression (28). The
TAp73b isoform also impinges on MYCN expression,
but via a distinct mechanism, as it leads to inhibition of
MYCN promoter activity. These observations indicate
that, unlike the N-terminal TA domain, the C-terminal
region of the p73 protein contains domains which are
essential for the transcriptional activation of MYCN.
As both TAp73a and Np73a isoforms inhibit MYCN
mRNA stability, the N-terminal TA domain of the p73
protein appears, as for the transcriptional activation of
MYCN, dispensable for this post-transcriptional repres-
sive function. On the contrary, the TAp73b isoform does
not signiﬁcantly alter MYCN transcript half-life, indicat-
ing that some motifs in the p73 protein C-terminal region
are implicated in this post-transcriptional inhibition of
MYCN. Site-directed point mutagenesis in that region
will help to further specify the p73 domains involved
and the molecular mechanism underlying this post-tran-
scriptional inhibition of MYCN. This post-transcriptional
inhibition exerted by p73 on MYCN does not extend to
closely related genes such as c-MYC, thus indicating a
relative speciﬁcity of this regulation.
The absence of physical binding between p73 and
MYCN promoter, revealed by ChIP experiments, suggest
that MYCN gene transactivation by p73a isoforms is
indirect. It could be either due to interaction of p73 with
a transcriptional repressor, thus inactivated, or mediated
by a transcriptional target of p73. Alternatively, p73a iso-
forms may transactivate the MYCN promoter through
binding to regulatory DNA elements located outside of
the tested 1.2kb proximal promoter region.
RNA IP experiments indicate that an interaction
between the p73 protein and MYCN mRNA may be
involved in the post-transcriptional inhibitory eﬀects
exerted by p73 on MYCN. The C-terminal domain of
p73 is likely implicated in the post-transcriptional inhibi-
tion of MYCN. Indeed, the C-terminal truncated TAp73b
isoform leads to transcriptional repression of MYCN but
has no eﬀect on its transcript stability. This C-terminal
region of p73 contains notably a Sterile Alpha Motif
(SAM) domain, some of which being known to bind to
speciﬁc RNA sequences, termed SRE for SAM Response
Elements (11,29,30). However, the SAM domain of p73
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Nucleic Acids Research, 2008, Vol. 36, No. 13 4229lacks the basic amino-acids, and is thus distinct from
such SMAUG-like SAM domains. Further investigations,
such as the use of engineered p73 mutants with targeted
deletions, will determine the contribution of the SAM and
transactivation inhibitor (TI) C-terminal domains of p73
(Supplementary Figure S1) in the post-transcriptional
inhibition of MYCN. It has been reported that p53 can
bind to RNA through diﬀerent mechanisms (26). Three
main types of p53–RNA interactions have been proposed:
covalent linkage with 5.8S rRNA via aminoacid residue
S389 (31), non-covalent but sequence-speciﬁc binding with
CDK4 or FGF-2 mRNA (32,33), and non-covalent and
non-speciﬁc binding (34). In all cases, the C-terminal
domain of the p53 protein seems to be required for inter-
action with RNA (26). Binding of p73 to MYCN mRNA
could involve mechanisms similar to those involved in
p53–RNA interactions. However, it is important to note
that the C-terminal domains of p53 and p73 are diﬀerent.
Whatever the molecular mechanisms involved, the con-
tradictory eﬀects of p73 on MYCN transcription and tran-
script stability may reﬂect the necessity of a tight MYCN
protein levels balance to ensure neuronal progenitor
cells survival and diﬀerentiation. In the light of previous
studies on the physiopathological roles of MYCN (35),
disequilibrium in favour of MYCN expression abrogation
would lead to neuronal cell death, while an excess of
MYCN would trigger an oncogenic switch. In this respect,
one report suggested that inhibition of p73 expression
by MYCN could contribute to NB oncogenesis by allow-
ing cells to escape the growth-suppressing properties of
p73 (36). Given both MYCN and p73 are required for
neuronal cells survival and proliferation (37–39), one can
envisage, based on our observations, a coordinated action
of these two proteins during neuronal cells ontogenesis.
The respective contribution of p73 and MYCN proteins
to neuronal cells proliferation and survival could also
explain why qualitative p73 changes, rather than complete
loss of p73 function, are encountered during NB oncogen-
esis (8,9). The dual transcriptional activation and post-
transcriptional inhibition exerted by p73 on MYCN
expression, revealed in our present study, might be one
element in the sequence of biological events required for
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4230 Nucleic Acids Research, 2008, Vol. 36, No. 13neuronal homoeostasis. Alterations of transcriptional
and post-transcriptional eﬀects of p73 could thus also con-
tribute to NB oncogenesis by favouring MYCN overex-
pression. A recent work reported that, in HeLa cervix
carcinoma cells, the p73 protein is up-regulated upon
interferon-g treatment (16). A previous study showed
that, in NB cells, interferon-g treatment leads to MYCN
mRNA down-regulation, at least partly due to decreased
transcript stability (17). Based on our observations, we
suggest that the post-transcriptional regulation exerted
by interferon-g on MYCN in NB cells could be mediated
by p73a, further arguing in favour of the possible implica-
tion of this regulation in certain physiopathological pro-
cesses. In addition to the evidence provided in NB cell
lines by our study, the implication of the dual regulation
exerted by p73 on MYCN expression warrants further
investigation in normal and cancer cells in vivo, notably
using transgenic mouse models.
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